Please assess the completion status of the following clinical trial:

Trial Title: Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 Diabetes Mellitus of mor than 1year~* GFR less than 30 ml/min/1.73m2 or dialysis~* Age greater than 18years~* Entry blood glucose (fasting or random) greater than 180mg%~Exclusion Criteria:~* Type 1 Diabetes Mellitus~* New onset hyperglycemia~* Pregnant~* Solid organ transplant within 1 year~* Steroids prednisone greater than 7.5mg/day or equivalent~* Hospital LOS predicted less than 2 days~* Severe liver disease~* Known hypopituitarism or adrenal insufficiency~* Patients in the ICU~* Patients with hypoglycemic unawareness~* Outpatient insulin dose less than 0.6 units/kg

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 0.5 units/kg (Type: ACTIVE_COMPARATOR): Participants randomized to this arm will receive a standard-dose of 0.5 units/kg daily insulin. Half of this dose will be given as glargine and the other half will be given as glulisine.
- 0.25 units/kg (Type: EXPERIMENTAL): Participants randomized to this arm will receive an experimental dose of 0.25 units/kg daily insulin. Half of this dose will be given as glargine and the other half will be given as glulisine.

Based on this trial design, predict the completion outcome and termination type (if applicable).